<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693966</url>
  </required_header>
  <id_info>
    <org_study_id>580299/005</org_study_id>
    <nct_id>NCT00693966</nct_id>
  </id_info>
  <brief_title>Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females</brief_title>
  <official_title>A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study is to provide data regarding the safety and immunogenicity
      for a range of dose levels of MEDI-517 in women who are HPV-16/18 seronegative and negative
      for high-risk HPV DNA. The study is designed to evaluate safety and immunogenicity data for
      MEDI-517 when formulated with either AS04 or aluminum hydroxide. Extended follow-up will
      provide long-term immune response data.

      This study was originally performed by MedImmune. However, GSK is now responsible for the
      clinical development of the HPV vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II double-blind, randomized, dose-comparison, multicenter study in the United
      States of three different dose levels of MEDI-517 (HPV-16/18 VLP AS04 vaccine) and one dose
      of MEDI-517 formulated with aluminum hydroxide, with doses administered at 0, 30 and 180
      days. Healthy female volunteers 18 through 30 years of age will be entered into 4 treatment
      arms. The objectives of study are to evaluate reactogenicity, safety and immunogenicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited adverse event rates (including injection site and systemic reactions)</measure>
    <time_frame>For 7 days after each injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse event rates</measure>
    <time_frame>For 30 days after each injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse event rates</measure>
    <time_frame>From first injection through 30 days after last injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory assessments (Biochemistry and Hematology parameters)</measure>
    <time_frame>Study Days 0, 30 and 210</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs (temperature, blood pressure, pulse rate, respiratory rate)</measure>
    <time_frame>At the time of injection and 30 minutes after the injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum ELISA titers against HPV-16 and HPV-18</measure>
    <time_frame>30 days after the third injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum ELISA titers against HPV-16 and HPV-18</measure>
    <time_frame>Study Days 0, 7, 30, 60, 180, 210, and 360, and at 24, 36, and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralization titers against HPV-16 and HPV-18</measure>
    <time_frame>Study Days 0, 60, 210 and 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immunity by IL-5, IFN-γ and lymphoproliferative assays</measure>
    <time_frame>Study Days 0, 60, 210, and 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV-16 and HPV-18 ELISA and inhibitory ELISA</measure>
    <time_frame>Study Days 0, 60, 210, and 360, and at 18, 24, 36, and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical and vaginal ELISA titers against HPV-16 and HPV-18</measure>
    <time_frame>At Study Days 210 and 360</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 2 of the vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 3 of the vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 4 of the vaccine [with Al(OH)3]</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)</other_name>
    <other_name>MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)</other_name>
    <other_name>MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18 through 30 years of age (must not have reached the 31st birthday)

          -  Unless previously surgically sterilized, agrees to use an effective method of birth
             control beginning 30 days before the first study injection and continuing through 60
             days after the final study injection

          -  Healthy by medical history and physical examination

          -  Seronegative for HPV-16 and HPV-18 antibody by ELISA within 21 days of study entry

          -  Cervical specimen negative for high-risk HPV DNA using the Digene Hybrid Capture® II
             HPV test (high-risk types Probe B) within 21 days of study entry

          -  Normal Pap smear, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry

          -  No evidence of anogenital HPV lesions or no physical findings suggestive of other
             gynecologic pathogens on pelvic examination within 21 days of study entry

          -  Agrees to no other experimental therapy or vaccines until 30 days after the last study
             injection

          -  Written informed consent obtained from the volunteer

        Exclusion Criteria:

          -  Acute illness or fever (oral temperature ≥ 99.5°F [37.5°C]) at start of the study

          -  History or clinical manifestations of significant medical or psychiatric disorder

          -  Pregnant or lactating

          -  Use of immunosuppressive medication within the previous 90 days or history of
             immunodeficiency

          -  History of cancer

          -  History of alcohol or drug abuse within the past 2 years

          -  Abnormal laboratory values in the screening panel which in the opinion of the
             principal investigator are judged to be clinically significant

          -  Receipt of immunoglobulin or blood products within 90 days prior to study entry

          -  History of abnormal Pap smear (other than a single prior report of ASCUS or
             indeterminate Pap smear with a subsequent normal report)

          -  Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1
             antibody

          -  Any prior receipt of any vaccine (experimental or otherwise) for treatment or
             prophylaxis of genital warts or other papillomavirus related condition. Any treatment
             of genital warts or other papillomavirus related condition within 6 months of
             randomization (local therapy for common skin and/or plantar warts is allowed)

          -  Previous administration of any components of the investigational vaccine

          -  Receipt of any experimental vaccine within 90 days prior to entry into this study

          -  Receipt of any experimental drug therapy within 30 days or five half-lives of the
             experimental drug (if the half-life is known), whichever is longer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009 May;5(5):332-40. Epub 2009 May 20.</citation>
    <PMID>19221517</PMID>
  </reference>
  <reference>
    <citation>Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 Aug 14;24(33-34):5937-49. Epub 2006 Jun 19.</citation>
    <PMID>16828940</PMID>
  </reference>
  <reference>
    <citation>Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049.</citation>
    <PMID>18845199</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV, Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>580299/005</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/005</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/005</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/005</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/005</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>580299/005</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

